Medical Groups Rename PCOS to PMOS, Citing 75% Insulin-Resistance Risk in Normal-Weight Patients
Updated
Updated · Baptist Health South Florida · Aug 17
Medical Groups Rename PCOS to PMOS, Citing 75% Insulin-Resistance Risk in Normal-Weight Patients
3 articles · Updated · Baptist Health South Florida · Aug 17
Summary
June 2026 brought an official shift from Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome, as medical organizations moved to reflect the disorder’s whole-body endocrine and metabolic effects.
The change aims to fix confusion caused by the old name: many patients lacked ovarian cysts on ultrasound yet still met hormonal criteria, delaying diagnosis and narrowing care to fertility rather than systemic risk.
Up to 75% of normal-weight patients with PMOS have underlying insulin resistance, doctors said, linking the condition to diabetes, hypertension, cardiovascular disease, stroke risk and endometrial complications if unmanaged.
Diagnosis still relies on clinical review and Rotterdam criteria rather than a single test, while treatment spans lifestyle changes, birth control, spironolactone, metformin and newer GLP-1 drugs such as semaglutide and tirzepatide.
Clinicians said the broader PMOS label could also improve multidisciplinary care, insurance coverage and research funding by framing the condition as a chronic metabolic disorder, not only a reproductive one.